• Aurinia reached a settlement with Teva over U.S. patent litigation tied to Teva’s planned generic voclosporin 7.9 mg capsules.
• Teva stipulated Aurinia U.S. Patent Nos. 10,286,036 and 11,622,991 are valid, enforceable, expire December 2037.
• Generic launch barred before Dec. 7, 2036, unless defined contingencies trigger earlier entry.
• U.S. marketing remains contingent on FDA approval for Teva’s generic voclosporin product.
• Separate patent suits continue in New Jersey against other generic challengers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608191605BIZWIRE_USPR_____20260819_BW509870) on August 19, 2026, and is solely responsible for the information contained therein.